- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01718756
Continuous Lornoxicam Infusion for Orthopaedic Surgery
Efficacy of Continuous Intravenous Infusion vs. Scheduled Dosing of Lornoxicam on Patient Controlled Morphine Consumption After Orthopaedic Surgery: A Comparative Placebo Study
Perioperative continuous infusion of lornoxicam would be an effective and safe regimen to reduce the patient controlled morphine consumption after orthopaedic surgery.
After ethical approval, 96 patients scheduled for elective orthopaedic fracture surgery under general anaesthesia were randomly allocated to receive placebo, 12-hourly iv lornoxicam 16 mg or lornoxicam 16 mg followed with continuous infusion of 1.3 mg/hr., for 48 hours after surgery (n=32 per group). Anaesthesia was induced with propofol, sufentanil and rocuronium, and was maintained with 0.5-1 minimum alveolar concentration sevoflurane, sufentanil and rocuronium. Postoperative patient controlled morphine analgesia was used. Changes in heart rate, mean blood pressure and sevoflurane minimum alveolar concentration, visual analogue pain scores, and cumulative patient controlled morphine consumptions and blood loss for 48 hours, platelet functions, bone non-union and the presence of adverse effects were recorded.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An independent investigator who was not involved in the study instructed the patients preoperatively about the use of visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and100 mm for worst imaginable pain) and about the use of PCA for their postoperative pain management.
Anaesthetic management was standardized. Oral lorazepam 2 mg was given the night before surgery. Subjects were allocated randomly into three groups (n = 32 for each) by drawing sequentially numbered sealed opaque envelopes containing a software-generated randomization code (Random Allocation Software, version 1.0.0, Isfahan University of Medical Sciences, Isfahan, Iran)into the placebo, scheduled, and continuous infusion groups. The syringes containing placebo and lornoxicam solutions were masked by identical opaque identical cover sheets. The test solution was prepared by one anaesthesiologist before induction of anaesthesia. Another anaesthesiologist, who was blinded to the study solution, gave the anaesthetic and was instructed to avoid using local anaesthetics, and a third anaesthesiologist collected perioperative data. All staff in the operating room were unaware of patient allocation group.
Patient monitoring included electrocardiography, non-invasive blood pressure, pulse oximetry, end-tidal sevoflurane and carbon dioxide (ETCO2) concentrations, response entropy (RE) and state entropy (SE.
After preoxygenation for 3 min, anesthesia was induced with fentanyl 1 - 3 µg/kg, propofol 1.5-2.5 mg/kg (to achieve an SE <50 and a difference<10 between RE and SE; RE-SE) and rocuronium 0.6 mg/kg. Tracheal intubation or slipping of laryngeal mask appropriate for body weight were used according to the discretion of the attending anaesthetist. Anaesthesia was maintained with a 0.6-1 minimum alveolar concentration of sevoflurane (MAC-Sevo) with air in 40% oxygen and fentanyl 1 µg/kg boluses to maintain SE <50 and RE-SE <10 and heart rate and mean arterial blood pressure within 20% of their baseline values. Rocuronium 0.1 mg/kg was given to maintain suppression of the second twitch using a train-of-four stimulation. The patients' lungs were ventilated to maintain an ETCO2 of 30-35 mmHg. Sevoflurane were discontinued at the start of skin closure, residual neuromuscular block was antagonized and the trachea extubated.
Postoperative analgesia was achieved according to the hospital protocol with patient controlled morphine analgesia (1 mg/ml), 1 mg, with a lockout interval of 8 minutes and a maximum 24-hourly limit of 180 mg. respiratory depression defined as the decrease in respiratory rate below 8/min was treated with i.v naloxone 0.2 mg. Nausea and vomiting were treated with i.v granisetron 1 mg and pruritus was treated with i.m promethazine 25 mg.
Heart rate and mean arterial blood pressure were recorded before (baseline) and 10 min after the start of infusion; every 30 min during surgery; every 15 min during the stay in post anaesthesia care unit (PACU), and 8 hourly for the following 48 hours. MAC-Sevo was recorded every 15 min after intubation until the end of surgery. Intraoperative fentanyl consumption was recorded.
The VAS pain scores, the presence and intensity of postoperative sedation (four-point verbal rating scores (VRS): awake, drowsy, rousable or deep sleep), nausea and vomiting (0: no nausea; 1: nausea no vomiting; 2: nausea and vomiting), were reported every 15 min for the first postoperative hour and two-hourly thereafter for the first 48 postoperative hours. The cumulative morphine consumption during the first 24 and 48 postoperative hours were recorded.
Platelet function assay was performed before and every 24 hrs. for the first three days after surgery. Cumulative intraoperative and postoperative blood loss and the number of transfused blood units were recorded. The presence of fracture non-union was reported.
All patients were observed by an independent investigator during the study period for the presence of nausea, vomiting, gastritis, reflux esophagitis, headache, bleeding, bronchospasm, sweating, allergy, thrombocytopenia, bleeding, ecchymosis, or increases in liver transaminases.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
DK
-
Mansoura, DK, Egypt, 050
- Anesthesiology Dept., College of Medicine, Mansoura University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists physical class I to III
- Age from 18 to 55 years
- Closed non comminuted long bone fractures
- Elective orthopaedic fracture surgery
- General anaesthesia
Exclusion Criteria:
- Hypersensitivity to lornoxicam
- Gastrointestinal ulceration or bleeding
- Cardiac diseases
- Pulmonary diseases
- Hepatic diseases
- Renal diseases
- Clotting diseases
- Bleeding diseases
- Bronchial asthma
- Diabetes mellitus
- Peripheral arterial occlusive disease
- Morbid obesity
- Pregnancy
- Alcohol or drug abuse
- Receiving other NSAIDs a day before surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
|
The placebo group received 12 hourly 20-mL i.v.
boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
|
Active Comparator: Scheduled
They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
|
The "scheduled" group received an 12 hourly 20-mL i.v.
boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia.
|
Active Comparator: Continuous infusion
They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs.
after surgery.
|
The "continuous infusion" group received 20-mL i.v.
boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v.
boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs.
after surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postoperative patient controlled morphine consumption
Time Frame: 24 hours and 48 hours after surgery
|
The cumulative morphine consumption during the first 24 and 48 postoperative hours were recorded.
|
24 hours and 48 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of analgesia
Time Frame: every two hours for 24 hours after surgery
|
the use of visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and100 mm for worst imaginable pain)
|
every two hours for 24 hours after surgery
|
platelet functions
Time Frame: daily after surgery for three days
|
daily after surgery for three days
|
|
Bone non-union
Time Frame: for 3 months after surgery
|
for 3 months after surgery
|
|
postoperative sedation
Time Frame: every two hours for 24 hours after surgery
|
four-point verbal rating scores (VRS): awake, drowsy, rousable or deep sleep),
|
every two hours for 24 hours after surgery
|
Nausea and vomiting
Time Frame: every two hours for 24 hours after surgery
|
nausea and vomiting (0: no nausea; 1: nausea no vomiting; 2: nausea and vomiting),
|
every two hours for 24 hours after surgery
|
Perioperative blood loss
Time Frame: Cumulative intraoperative and 24 hours after surgery
|
Cumulative intraoperative and 24 hours after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lornoxicam adverse effects
Time Frame: 48 hours after surgery
|
the presence of nausea, vomiting, gastritis, reflux esophagitis, headache, bleeding, bronchospasm, sweating, allergy, thrombocytopenia, bleeding, ecchymosis, or increases in liver transaminases.
|
48 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohamed R El Tahan, MD, College of Medicine, Mansoura University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R/55
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Closed Non Comminuted Long Bone Fractures
-
Chinese University of Hong KongCompletedFracture, Closed, Comminuted, HealingChina
-
Technical University of MunichCompletedFracture, Closed, Comminuted, HealingGermany
-
Fundacion Clinica Valle del LiliCompletedFracture, Closed, Comminuted, HealingColombia
-
Rabin Medical CenterUnknownClosed Comminuted Oblique Intertrochanteric Fracture of Neck of Right Femur | Closed Comminuted Oblique Intertrochanteric Fracture of Neck of Left FemurIsrael
-
Cairo UniversityCompleted
-
Cairo UniversityCompletedClavicle Fracture | Bone Fracture | Bone LesionEgypt
-
Inova Health Care ServicesDePuy SynthesTerminatedTibial FracturesUnited States
-
Insel Gruppe AG, University Hospital BernRecruitingFracture Tibia | Fracture Femur | Fracture, ComminutedSwitzerland
-
Bone Therapeutics S.ATerminatedLong Bone Non-UnionBelgium, France, Netherlands
-
Herlev and Gentofte HospitalRecruitingIntra-Articular Fractures | Distal Humerus Fracture | Comminuted FractureDenmark
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States